CRISPR CFO’s 10b5‑1 Trades: Buying Low, Selling High Signals Quiet Insider Bullishness
Insider CFO Prasad Raju’s 10b5‑1 trades show confidence in CRISPR Therapeutics; buying near $45‑$44 while selling above $60 signals a bullish, medium‑term outlook for the gene‑editing stock.
3 minutes to read